BERLIN, Sept. 12, 2025 /PRNewswire/ — Every September, the world of consumer tech gathers in Berlin for IFA, one of the largest technology trade shows in the world. 2025 marks Antigravity’s first entry onto the scene.

Antigravity’s First-Ever Public Appearance

IFA 2025 marked the public debut of Antigravity A1, the world’s first 8K 360 drone.^[1] Sharing a big booth with Insta360, Antigravity let thousands of visitors experience immersive drone flight firsthand. The combination of A1, the Vision goggles, and Grip controller allowed visitors to immerse themselves in the future of flight.

The response was overwhelming, with visitors expressing excitement over A1’s capabilities, many referring to it as a game changer and industry disruptor. With many looking forward to being able to tell new stories with the unique combination of technologies in A1. Others were excited that they could share memories in new and immersive ways.

Recognition From the Industry

Antigravity A1 received 18 industry awards at IFA 2025, including several Best of IFA titles from leading outlets such as Wired, Tom’s Guide and TechRadar. The recognition highlights A1’s breakthrough combination of 360 capture, intuitive control, and advanced flight technology.

Looking Ahead

Antigravity’s debut comes at a pivotal moment for the drone industry, where innovation has slowed. With the A1, Antigravity is redefining aerial exploration and setting a new standard for immersive flight experiences.

“Antigravity A1 makes high-quality drone footage simple for anyone to capture,” said Jason England of Tom’s Guide.

IFA 2025 is just the beginning. Antigravity will showcase A1 at additional global trade shows in the months ahead, ensuring more people can experience what is already being called one of the most exciting drones in years.

About Antigravity

Antigravity is a consumer drone company reimagining how people experience flight. Incubated by Insta360 in collaboration with third parties, Antigravity develops powerful 360 drones that are immersive, creator-ready, and easy for anyone to fly — whether capturing family moments, weekend adventures, or creative projects.

Antigravity on Social Media

YouTube
Instagram
Facebook
X (formerly Twitter)
TikTok
LinkedIn

^[1]The term world’s first refers to the fact that, as of July 28, 2025, Antigravity has announced the market’s first 8K all-in-one 360 drone. It captures high-quality 360 video directly without the need for an external 360 camera attachment. The drone features a built-in 360 camera, supports real-time data transmission, and allows users to adjust shooting parameters on the fly.

1^st Half revenue grew 452.1% to $32.3 million YoY

IM8 achieved $5.9 million revenue in August 2025, representing a CAGR^[1] of over 3,100%

Prenetics increases FY2025 revenue guidance range of $85 – $100 million

Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily

Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward

HONG KONG, Sept. 12, 2025 /PRNewswire/ — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2025, along with recent business updates.

Danny Yeung, Chief Executive Officer and Co-Founder remarked “This quarter marks a pivotal moment for Prenetics as we demonstrate the successful execution of our strategic vision. The phenomenal growth of IM8, which is on track to achieve an unprecedented $100 million in annual recurring revenue within just our first year of operations, represents a milestone that is virtually unheard of in any industry. With IM8 currently generating $5.9 million in monthly revenue in August, we aim to hit $9 million per month by the end of the year, which would solidify our path to this extraordinary achievement. With such strong growth momentum, we believe we can build IM8 into one of the World’s largest health and wellness brands in the coming years. Beyond the financial metrics, what makes me truly proud is the positive impact IM8 has had on so many people’s health and wellness journeys – with over 8 million servings delivered and more than 300,000 customer orders, we are genuinely making a difference in people’s lives.”

Danny further added “We’ve embraced a new strategic philosophy focused on optimizing both health and wealth – just as IM8 enhances people’s physical well-being, our disciplined Bitcoin treasury strategy is designed to enhance our financial well-being and create long-term value preservation for our shareholders. We are not just building a successful health sciences company; we are building a company that is forward-thinking and resilient. With a strong balance sheet of $90 million in cash and BTC, a clear path to profitability in early 2026, and multiple avenues for growth, we are more confident than ever in our ability to deliver significant and sustainable long-term value to our shareholders.”

Second Quarter 2025 Financial Highlights^[2]

• Revenue of $17.7 million in the second quarter of 2025, an increase of 594.9% as compared to the second quarter of 2024.
• Gross profit of $7.3 million in the second quarter of 2025, an increase of 233.5% as compared to the second quarter of 2024.
• Adjusted EBITDA^[3] loss of $(4.1) million in the second quarter of 2025, a decrease of 8.7% as compared to the first quarter of 2025.
• Loss of $(10.9) million in the second quarter of 2025, an increase of 22.7% as compared to the second quarter of 2024.
• Adjusted current assets^[4] were $90.3 million, including $63.5 million of cash. As of September 10, 2025, the Company held 228.42 Bitcoin^[5] with a value of $26.1 million and remained debt-free.

Second Quarter Business Unit Revenue Breakdown:

• IM8 – $9.8 million (Increase of 70% over Q1)
• Europa – $5.7 million
• CircleDNA – $2.2 million

First Half 2025 Financial Highlights

• Revenue of $32.3 million in the first half 2025, an increase of 452.1% as compared to the first half 2024.
• Gross profit of $13.2 million in the first half 2025, expanded by 166.4% as compared to the first half 2024.
• Adjusted EBITDA loss of $(8.7) million in the first half 2025, an increase of 45.4% as compared to the first half 2024.
• Loss of $(19.8) million in the first half 2025, an increase of 30.2% as compared to the first half 2024.

First Half Business Unit Revenue Breakdown:

• IM8 – $15.5 million
• Europa – $12.0 million
• CircleDNA – $4.8 million

Business Updates and Strategic Initiatives

IM8 Strong Business Momentum:

IM8 Health, a brand 100% wholly owned by Prenetics, has rapidly emerged as one of the fastest-growing supplement brands globally since its launch in December 2024. The brand’s high-profile status with David Beckham as its co-founding partner is further bolstered by its multi-year partnership with Aryna Sabalenka, the World No. 1 tennis player and 2025 US Open champion, who serves as a global ambassador and Prenetics shareholder. The brand’s marketing prowess was demonstrated during the US Open with an AI-powered Aryna Sabalenka video that went viral on Instagram, generating an extraordinary 233 million views. The campaign also featured prominently on the iconic Times Square billboard throughout the US Open and will continue running through the end of September, showcasing IM8’s ability to capture global attention and drive brand awareness at scale.

IM8 has further strengthened its scientific advisory board with the addition of Dr. Darshan Shah, a leading regenerative medicine physician and longevity expert; Dr. Ara Suppiah, a renowned sports medicine specialist and performance optimization physician; and Simon Hill, a prominent nutritionist and plant-based nutrition advocate. Looking ahead, the company is very excited about its new upcoming products, which will be best-in-class from a science perspective, further strengthening IM8’s position as a leader in premium nutrition and longevity solutions.

IM8 has demonstrated exceptional growth, with monthly net revenue surging from $581,000 in December 2024 to $5.9 million in August 2025, representing a compound annual growth rate (CAGR)^[1] of over 3,100%. This remarkable performance is underscored by strong underlying business fundamentals and a highly efficient customer acquisition strategy. In the first half of 2025, IM8 Health achieved a 80%+ new customer subscription rate and an average order value of $110, reflecting strong customer loyalty and high-value transactions. With a gross margin of 52% and a customer acquisition cost of $104 in the first half of 2025, the brand’s unit economics are compelling, further evidenced by an implied LTV/CAC ratio of 4.8x. To date, IM8 has processed more than 300,000 customer orders and delivered more than 8 million servings of its flagship product, IM8 Daily Ultimate Essentials, solidifying its position as a significant player in the crowded health and wellness market.

IM8 Health – Key Performance Indicators (1H 2025 unless otherwise indicated)

Strategic Bitcoin Treasury Initiatives:

Leveraging our strong cash position and robust business fundamentals, we initiated a disciplined treasury reserve program in the second quarter, starting with an initial $20 million purchase of 187.42 BTC at an average price of $106,712 BTC in June 2025. This was followed by our programmatic daily accumulation of Bitcoin as a primary treasury reserve asset, funded directly from our operating cash beginning on August 1, 2025. As of September 10, 2025, the company holds 228.42 BTC on its balance sheet, acquired at an overall average price of approximately $108,131 per BTC. At the current Bitcoin price of $115,105, this position reflects an unrealized gain of approximately $1.6 million, equating to an annualized yield of roughly 30% since the initiation of our program in June 2025.

Looking ahead, we plan to continue our disciplined approach with daily acquisitions of 1 BTC through the remainder of 2025⁶, with expectations to further increase our accumulation rate in 2026 as our cash generation continues to strengthen. Additional purchase will be funded from available cash flows while maintaining prudent operating liquidity. This strategic move reflects our conviction in Bitcoin as a superior store of value and a compelling, non-correlated asset with significant long-term appreciation potential. By systematically converting a portion of our cash flows into Bitcoin, we are not only preserving our capital against inflationary pressures but also positioning Prenetics to capture the asymmetric upside of this emerging asset class. We believe this proactive and forward-thinking treasury management approach will enhance our financial strength and create substantial long-term value for our shareholders.

To further enhance transparency, we have launched a dedicated Bitcoin Treasury Analytics page, which provides real-time updates on our holdings and performance, available at: https://www.prenetics.com/btc 

Business Outlook

Prenetics increases full-year 2025 guidance range of $85 – 100 million in revenue and expects to achieve breakeven by Q1 2026. Our combination of disciplined execution in consumer health, strengthening brand equity at IM8, a flexible capital markets posture, and strong balance sheet positions Prenetics to deliver significant growth.

Breakdown of Full-Year Business Unit Revenue Guidance:

• IM8: $55 – $60 million
• Europa: $20 – $25 million
• CircleDNA: $10 – $15 million

ACT Genomics Divestment

We announced on June 18, 2025 on the divestment of ACT Genomics to Delta Electronics, Inc for a total transaction value of approximately $71.8 million, with a gross proceeds to Prenetics of $46.3 million as settlement. Closing is progressing as planned and is expected in Q4 2025. In line with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, ACT Genomics has been classified as a disposal group held for sale and a discontinued operation. Accordingly, its results are presented separately from continuing operations, and prior-period comparatives have been re-presented for consistency.

About Prenetics

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World’s fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. To learn more please visit www.prenetics.com and www.IM8health.com. 

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. 

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including revenue ranges and breakdown timing) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company’s ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Basis of Presentation

Prior year/ period figures have been re-presented in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, as result of the ACT Genomics divestment, the Group has classified ACT Genomics as held for sale and discontinued operations in June 2025.

Unaudited Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading “Unaudited Non-IFRS Financial Measures”.

Unaudited Non-IFRS Financial Measures

To supplement Prenetics’ consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), the Company is providing non-IFRS measure, adjusted EBITDA loss from continuing operations. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company’s ongoing operating results and trends.

Management is excluding from some or all of its non-IFRS results (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company’s public disclosures.

In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company’s non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned “Reconciliation of loss for the period under IFRS and adjusted EBITDA loss (Non-IFRS)”, “Revenue by business unit from continuing operations (Non-IFRS)” and “Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)” set forth at the end of this document.

Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)

—————————————————————————

^[6] Includes equity-settled share-based payment expenses from continuing operations as follows:

^[7] ACT Genomics Holdings Company Limited (“ACT Genomics”) are classified as discontinued operations in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations (“IFRS 5”). In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.

BEIJING, Sept. 12, 2025 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi) (“WiMi” or the “Company”), a leading global Hologram Augmented Reality (“AR”) Technology provider, today announced an in-depth study of the multidimensional pooling optimization technique in variational quantum algorithms. By introducing the Quantum Haar Transform (QHT) and quantum partial measurement, they provided a novel solution for multidimensional data pooling. The Haar transform is a classical signal processing technique used for data compression and feature extraction. The Quantum Haar Transform (QHT) is its extension within the quantum computing framework, which leverages the superposition and entanglement properties of quantum states to efficiently transform multidimensional data.

Through QHT, multidimensional data is mapped to a quantum state space, where each qubit represents a dimension or feature of the data. This mapping not only preserves the global structure of the data but also enhances the expression of local features. After the Quantum Haar Transform, quantum partial measurement techniques can selectively extract key information from the quantum state, enabling the pooling operation for multidimensional data. Unlike traditional pooling methods that directly discard part of the data, quantum partial measurement leverages the probabilistic nature of quantum states to retain the most important feature information in probabilistic form, according to predefined pooling strategies (such as max pooling, average pooling, etc.). This process not only reduces the data dimensionality but also preserves the locality and key features of the data, providing high-quality input for subsequent quantum classification or regression tasks.

Variational Quantum Algorithms (VQA) are hybrid algorithms that combine quantum computing and classical optimization. By using parameterized quantum circuits and optimization techniques such as gradient descent, VQAs iteratively adjust quantum states to minimize a given loss function. In multidimensional pooling optimization, VQA is used to optimize parameters, ensuring that the pooling operation can accurately capture key features of the data while maintaining computational efficiency and accuracy. Through an iterative optimization process, VQA continually adjusts the parameters of the quantum circuit so that the quantum state transformation and measurement process can maximally preserve the locality and feature structure of the data. Moreover, VQAs can directly perform pooling operations on multidimensional data without the need to reduce the data to one dimension, effectively retaining the locality and structural information of the data. The superposition and entanglement properties of quantum states enable more rich representations of multidimensional data in quantum space, helping to extract finer and more complex features. The utilization of quantum parallelism and entanglement allows VQA to significantly accelerate computation when handling large-scale multidimensional data, improving the efficiency of model training and inference. The VQA framework is highly scalable and can accommodate various types of multidimensional data processing needs, ranging from one-dimensional audio data to two-dimensional image data and even three-dimensional hyperspectral data. By adjusting the parameters and structure of the quantum circuit, VQA can be flexibly applied to different dimensional data processing tasks.

The multidimensional pooling optimization technology under the Variational Quantum Algorithm framework researched by WiMi provides a new solution for quantum machine learning in handling complex multidimensional data tasks. It not only overcomes the limitations of traditional pooling methods when dealing with high-dimensional data but also fully leverages the unique advantages of quantum computing. As quantum computing technology continues to develop and mature, the multidimensional pooling optimization technology under the VQA framework is expected to demonstrate its enormous application potential and value in more fields. In the future, with improvements in quantum hardware and algorithm optimization, this technology is expected to provide strong support for building more efficient and accurate quantum machine learning models.

About WiMi Hologram Cloud

WiMi Hologram Cloud, Inc. (NASDAQ:WiMi) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains “forward-looking statements” within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission (“SEC”) on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

SHENZHEN, China, Sept. 12, 2025 /PRNewswire/ — MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), is a technology service provider. Because traditional quantum estimation methods often struggle to capture accurate parameter information, how to achieve high-precision estimation in such a dynamic oscillation environment became the core goal of the study. They conducted in-depth research on this issue, focusing on a system of two different superconducting qubits coupled by a fixed capacitor, and explored a technical pathway to achieve high-precision estimation even in the presence of quantum oscillations, providing important references for quantum circuit design and the development of quantum metrology.

To achieve high-precision quantum parameter estimation, HOLO innovatively introduced Quantum Fisher Information (QFI) and Hilbert-Schmidt Speed (HSS) as core analytical tools, proposing a complete quantum estimation technology framework. Quantum Fisher Information, as the gold standard in quantum metrology, can quantify the theoretical limit of precision for parameter estimation, with its numerical value directly corresponding to the lower bound of the minimum estimation error for the parameter. Meanwhile, Hilbert-Schmidt Speed, from the geometric perspective of the quantum state space, describes the “speed level” of quantum states with respect to the parameter to be estimated, providing a new perspective for parameter estimation in dynamically evolving systems. In systems with quantum oscillations, QFI can capture the redundant parameter information contained in the quantum state during the oscillation process, while HSS effectively characterizes the dynamic sensitivity of quantum state evolution in an oscillating environment. The combination of the two forms a complementary estimation tool, providing theoretical support for overcoming oscillation interference.

Specifically, HOLO systematically analyzed the impact of Josephson junction arrangements on quantum estimation performance through a combination of numerical simulations and theoretical derivations. The study found that the series and parallel structures of Josephson junctions lead to differences in the equivalent inductance and capacitance of qubits, which in turn affect the system’s transition frequency and the range of detuning control. When Josephson junctions are arranged asymmetrically, the quantum oscillation frequency of the system exhibits richer modulation characteristics. Although this characteristic increases the complexity of state evolution, it also provides more information dimensions for QFI and HSS—by selecting an appropriate evolution time window, QFI can exhibit local peaks within the oscillation period, while HSS can reach its maximum at specific phases of the oscillation. The synergistic effect of the two enables the extraction of high-precision parameter information even in a continuously oscillating environment.

Josephson Parametric Amplifiers (JPAs), as key devices for amplifying weak signals in quantum circuits, have performance that directly depends on the parameter design of superconducting quantum systems, and HOLO’s research results provide important guidance for JPA optimization. The core working principle of JPAs is to utilize the nonlinear inductance of Josephson junctions to achieve parametric amplification, with their gain, bandwidth, and noise performance closely related to parameters such as the system’s detuning and coupling strength. By quantitatively evaluating these parameters using QFI and HSS, the optimal operating condition of JPAs can be precisely identified: when the system’s detuning is within a specific range, even in the presence of quantum oscillations, QFI can maintain a high value, indicating that high-precision estimation of the amplifier’s key parameters can be achieved at this point, thereby guiding the structural optimization of JPAs and enhancing their performance in quantum signal detection.

HOLO constructed a superconducting qubit simulation model to simulate the quantum oscillation behavior of the system under different Josephson junction arrangements and calculated the corresponding QFI and HSS values. The results show that in cases of large quantum oscillation amplitudes, by optimizing the measurement timing and parameter control strategies, the peak value of QFI can be improved by more than 30%, and HSS also exhibits a significant enhancement in sensitivity. This indicates that quantum estimation precision can indeed be effectively improved in an oscillating environment. This result challenges the traditional notion that “quantum oscillations inevitably lead to a decrease in estimation precision,” opening new directions for the application of quantum metrology in dynamic systems, particularly providing significant reference value for the design of devices such as quantum sensors and quantum gyroscopes that need to operate in complex quantum environments.

HOLO’s research not only successfully addressed the challenge of parameter estimation in the presence of quantum oscillations in superconducting quantum systems but also proposed a theoretical framework for estimation in dynamic quantum systems through the innovative application of Quantum Fisher Information and Hilbert-Schmidt Speed. As quantum technology continues to advance, the technical pathway proposed in this study is expected to find applications in a broader range of quantum systems, laying a solid foundation for high-precision quantum measurement and quantum information processing.

About MicroCloud Hologram Inc.

MicroCloud is committed to providing leading holographic technology services to its customers worldwide. MicroCloud’s holographic technology services include high-precision holographic light detection and ranging (“LiDAR”) solutions, based on holographic technology, exclusive holographic LiDAR point cloud algorithms architecture design, breakthrough technical holographic imaging solutions, holographic LiDAR sensor chip design and holographic vehicle intelligent vision technology to service customers that provide reliable holographic advanced driver assistance systems (“ADAS”). MicroCloud also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud’s holographic digital twin technology resource library captures shapes and objects in 3D holographic form by utilizing a combination of MicroCloud’s holographic digital twin software, digital content, spatial data-driven data science, holographic digital cloud algorithm, and holographic 3D capture technology. MicroCloud focuses on the development of quantum computing and quantum holography, and plans to invest over $400 million in cutting-edge technology sectors, including quantum computing technology development, quantum holography development, and the development of derivatives and technologies in artificial intelligence and augmented reality (AR).

For more information, please visit http://ir.mcholo.com/

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (“SEC”), including the Company’s most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.